Intravesical Recurrence after Surgical Management of Urothelial Carcinoma of the Upper Urinary Tract

Objectives: To elucidate clinicopathological risk factors for intravesical recurrence (IVR) in patients undergoing nephroureterectomy for upper urinary tract urothelial carcinoma (UUT-UC). Methods: We identified a study population of 151 consecutive patients without previous or concurrent bladder cancer who underwent nephroureterectomy for UUT-UC. IVR was assessed in relation to tumor location, size, and multifocality, operation modality and time, stage, grade, lymphovascular invasion, regional lymph node metastasis, preoperative urinary cytology, and perioperative chemotherapy. The median follow-up time was 24 months. Results: Of 151 patients, 51 (34%) developed IVR after nephroureterectomy, and 50 (98%) of the patients presented with IVR within 2 years. Tumor multifocality and site (located in ureter) were determined as risk factors for IVR by univariate analysis. In a multivariate analysis, only tumor multifocality (relative risk: 4.024, p = 0.001) was an independent predictor of IVR. Ten-year cancer-specific survival rates for the patients with and without IVR were 68 and 52%, respectively (p = 0.06). Conclusions: Tumor multifocality is a significant risk factor in developing IVR after surgery for UUT-UC. These results indicate that despite most IVR occurring within 2 years of treatment, it is necessary to follow such patients more closely using cystoscopy. However, IVR is unlikely to indicate a poorer prognosis.

[1]  T. O'brien,et al.  Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial). , 2011, European urology.

[2]  C. Kwak,et al.  Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract. , 2011, Urologic oncology.

[3]  C. Tulić,et al.  Bladder cancer after managing upper urinary tract transitional cell carcinoma: risk factors and survival , 2011, International Urology and Nephrology.

[4]  Chien-Feng Li,et al.  Primary urothelial carcinoma of the upper tract: Important clinicopathological factors predicting bladder recurrence after surgical resection , 2009, Pathology international.

[5]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[6]  L. Kiemeney,et al.  The present and future burden of urinary bladder cancer in the world , 2009, World Journal of Urology.

[7]  P. Tsai,et al.  Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. , 2008, European urology.

[8]  Y. Sugimura,et al.  Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma , 2008, International journal of urology : official journal of the Japanese Urological Association.

[9]  M. Babjuk,et al.  EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. , 2008, European urology.

[10]  Chao-yuan Huang,et al.  CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  K. Mita,et al.  Risk factors for intravesical recurrence following urothelial carcinoma of the upper urinary tract: no relationship to the mode of surgery. , 2007, Japanese journal of clinical oncology.

[12]  P. Rehak,et al.  Bladder tumour development after urothelial carcinoma of the upper urinary tract is related to primary tumour location , 2006, BJU international.

[13]  H. Ozen,et al.  Prognostic significance of bladder tumor history and tumor location in upper tract transitional cell carcinoma. , 2006, The Journal of urology.

[14]  S. Boorjian,et al.  Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology , 2005, BJU international.

[15]  K. Yoshimura,et al.  Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. , 2005, Urology.

[16]  M. Kattan,et al.  Bladder cancer as a prognostic factor for upper tract transitional cell carcinoma. , 2004, The Journal of urology.

[17]  R. Sylvester,et al.  A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. , 2004, The Journal of urology.

[18]  Y. Shiue,et al.  The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract , 2003, Cancer.

[19]  E. Tuzel,et al.  Transitional cell carcinoma of the ureter and renal pelvis. , 2003, Critical reviews in oncology/hematology.

[20]  R. Knuechel,et al.  Clonality of multifocal urothelial carcinomas: 10 years of molecular genetic studies , 2002, International journal of cancer.

[21]  N. Masumori,et al.  Risk factors for the development of bladder cancer after upper tract urothelial cancer. , 2000, Urology.

[22]  O. Yoshida,et al.  Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. , 1998, Cancer research.

[23]  R. Takahashi,et al.  Metachronous multifocal development of urothelial cancers by intraluminal seeding , 1993, The Lancet.

[24]  T. Kakizoe,et al.  Transitional cell carcinoma of the bladder in patients with renal pelvic and ureteral cancer. , 1980, The Journal of urology.

[25]  Jeff Davies.  Reproduced with the permission of Bird life Australia and , 2013 .

[26]  M. Babjuk,et al.  [EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update]. , 2012, Actas urologicas espanolas.

[27]  L. Tanoue.  Cancer Statistics, 2009 , 2010 .

[28]  H. Miyake,et al.  Risk factors for intravesical recurrence after surgical management of transitional cell carcinoma of the upper urinary tract. , 2008, Urology.

[29]  A. Marx,et al.  World Health Organization Classification of Tumors. Pathology and Genetics of Tumors of the Urinary System and Male Genital Organs , 2004 .

[30]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.